Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonya L Heltshe

Showing results (11-20 of 92) with videos related to

Pageof 10
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 8, 2013
Evaluating the predictive ability of sweat chlorideSonya L Heltshe, Steven M Rowe, Nicole Mayer-Hamblett
Annals of the American Thoracic Society|August 13, 2016
Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed TherapiesDonald R VanDevanter, Sonya L Heltshe, John J LiPuma
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 25, 2017
Use of FEV<sub>1</sub> in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcherRhonda Szczesniak, Sonya L Heltshe, Sanja Stanojevic, et al.
American Journal of Respiratory and Critical Care Medicine|October 7, 2016
Cystic Fibrosis: The Dawn of a New Therapeutic EraSonya L Heltshe, Jonathan Cogen, Kathleen J Ramos, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 21, 2023
Re-examining baseline lung function recovery following IV-treated pulmonary exacerbationsSonya L Heltshe, Renee Russell, Donald R VanDevanter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 8, 2020
Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosisDonald R VanDevanter, Sonya L Heltshe, Jay B Hilliard, et al.
American Journal of Respiratory and Critical Care Medicine|December 20, 2017
Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical ImprovementSonya L Heltshe, Steven M Rowe, Michelle Skalland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 12, 2014
Early attained weight and length predict growth faltering better than velocity measures in infants with CFSonya L Heltshe, Drucy S Borowitz, Daniel H Leung, et al.
Pediatric Pulmonology|April 16, 2021
Use of proton pump inhibitors is associated with lower hemoglobin levels in people with cystic fibrosisAlex H Gifford, Julie L Sanville, Meghana Sathe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 14, 2017
Pregnancy among cystic fibrosis women in the era of CFTR modulatorsSonya L Heltshe, Emily M Godfrey, Tatiana Josephy, et al.
Pageof 10

Showing results (11-20 of 92) with videos related to

Sort By:
Pageof 10
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 8, 2013
Evaluating the predictive ability of sweat chlorideSonya L Heltshe, Steven M Rowe, Nicole Mayer-Hamblett
Annals of the American Thoracic Society|August 13, 2016
Potential for Therapeutic Benefit among Cystic Fibrosis Populations Excluded from Clinical Trials or Labeling of Marketed TherapiesDonald R VanDevanter, Sonya L Heltshe, John J LiPuma
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 25, 2017
Use of FEV<sub>1</sub> in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcherRhonda Szczesniak, Sonya L Heltshe, Sanja Stanojevic, et al.
American Journal of Respiratory and Critical Care Medicine|October 7, 2016
Cystic Fibrosis: The Dawn of a New Therapeutic EraSonya L Heltshe, Jonathan Cogen, Kathleen J Ramos, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 21, 2023
Re-examining baseline lung function recovery following IV-treated pulmonary exacerbationsSonya L Heltshe, Renee Russell, Donald R VanDevanter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 8, 2020
Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosisDonald R VanDevanter, Sonya L Heltshe, Jay B Hilliard, et al.
American Journal of Respiratory and Critical Care Medicine|December 20, 2017
Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical ImprovementSonya L Heltshe, Steven M Rowe, Michelle Skalland, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 12, 2014
Early attained weight and length predict growth faltering better than velocity measures in infants with CFSonya L Heltshe, Drucy S Borowitz, Daniel H Leung, et al.
Pediatric Pulmonology|April 16, 2021
Use of proton pump inhibitors is associated with lower hemoglobin levels in people with cystic fibrosisAlex H Gifford, Julie L Sanville, Meghana Sathe, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 14, 2017
Pregnancy among cystic fibrosis women in the era of CFTR modulatorsSonya L Heltshe, Emily M Godfrey, Tatiana Josephy, et al.
Pageof 10